Amgen Inc Investor Call at European Society for Medical Oncology (ESMO) Transcript

Sep 28, 2019 / 05:00PM GMT
Operator

My name is Mary, and I will be your conference facilitator today for Amgen's Conference Call from the 2019 European Society for Medical Oncology in Barcelona. (Operator Instructions) I would now like to introduce Mr. John Shutter, Director of Investor Relations. Please go ahead, sir.

John Shutter -

Thank you, Mary, and thanks, everyone, for joining us today.

As you know, we provided a clinical update at ESMO on AMG 510, our first-in-class KRAS G12C inhibitor in patients with solid tumors that harbor this mutation.

I'm joined today by Dr. David Reese, our Executive Vice President of Research and Development; and by Dr. Greg Friberg, who's our Vice President of Global Oncology Development.

Dave will make some opening comments, and Greg will step through the data that were presented today, after which we'll take your questions.

And for the Q&A, I'm especially pleased to welcome Dr. Marwan Fakih, who is Professor in the Department of Medical Oncology and Therapeutics Research as well as Co-Director of the Gastrointestinal Cancer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot